---
title: 'TowardÂ a more patient-centered drug development process in clinical trials
  for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations
  from the International Consortium for MDS (icMDS)'
date: '2024-05-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38774655/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240523183254&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Notable treatment advances have been made in recent years for patients
  with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under
  development. For example, the emerging availability of oral MDS therapies holds
  the promise of improving patients' health-related quality of life (HRQoL). Within
  this rapidly evolving landscape, the inclusion of HRQoL and other patient-reported
  outcomes (PROs) is critical to inform the benefit/risk assessment of new therapies
  or to assess ...
disable_comments: true
---
Notable treatment advances have been made in recent years for patients with myelodysplastic syndromes/neoplasms (MDS), and several new drugs are under development. For example, the emerging availability of oral MDS therapies holds the promise of improving patients' health-related quality of life (HRQoL). Within this rapidly evolving landscape, the inclusion of HRQoL and other patient-reported outcomes (PROs) is critical to inform the benefit/risk assessment of new therapies or to assess ...